Such wealth of data paves the way to structure-based drug discovery campaigns where compounds designed to work as allosteric enhancers of the TPP1-TERT binding interaction might contrast telomeropathies like HHS, while compounds acting as allosteric inhibitors of the TPP1-TERT binary complex might represent a novel class of anticancer agents. This evidence concerns the gene TERT and hypotrichosis 1.